Adaptilens was awarded $75,000 in the 2022 President’s Innovation Challenge for developing an intraocular lens that restores the eye’s ability to focus, offering a revolutionary approach to vision correction.
Adaptilens was awarded $75,000 in the 2022 President’s Innovation Challenge for developing an intraocular lens that restores the eye’s ability to focus, offering a revolutionary approach to vision correction.
Adaptilens' CEO, Liane Clamen, joined an esteemed panel of CEOs to lead the MedTech CEO-Only Forum at #JPM25, hosted by Giovanni Lauricella, CEO of Lifeblood and Martin Gomez, Partner at Goodwin.
Read MoreAs we reflect on 2024, we're proud to spotlight over 130 remarkable achievements from our entrepreneurial community, driving innovation and impact across industries: • Adaptilens is developing an intraocular lens that responds to the eye's natural signal to focus, eliminating the need for eyeglasses or contact lenses. This year, the company raised $17.5 million in funding. • Akouos, a biotech company focused on restoring hearing in deaf children, was featured in The New York Times for helping a child hear for the first time. • IAMBIC is disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. In 2024, IAMBIC completed Techstars NYC, secured $1.25 million in non-dilutive federal and state funding, and expanded the team with seven key hires. Explore more inspiring accomplishments: https://lnkd.in/duWGZ5Kt
Read MoreAdaptilens was well represented at the Ophthalmology Innovation Source XIV in San Diego where our CEO Liane Clamen spoke on the panel "Future of Anterior Innovation: A Panel of Disruptors and Visionaries." Thank you Anthony Wallace - Bausch + Lomb Surgical for inviting our CEO and facilitating an inspiring discussion.
Read MoreFollow our progress on